January 30, 2018 / 6:18 AM / 5 months ago

BRIEF-Innate Pharma And Medimmune Enter Clinical Trial Collaboration

Jan 30 (Reuters) - INNATE PHARMA SA:

* INNATE PHARMA AND MEDIMMUNE ENTER CLINICAL TRIAL COLLABORATION

* COLAB TO EVALUATE COMBINATION OF IPH5401 ANTIBODY AND IMFINZI(®) (DURVALUMAB) IN A PHASE I/II STUDY FOR PATIENTS WITH SELECTED SOLID TUMORS

* INNATE WILL SPONSOR STUDY WITH COSTS EQUALLY SHARED BY BOTH PARTIES Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below